United States: Federal Circuit Clarifies PTA Calculation In Face Of RCE, Interference

Last Updated: September 24 2019
Article by Clyde A. Shuman

The Federal Circuit has held that where a request for continued examination (“RCE”) has been filed, the time between termination of an interference and mailing of the Notice of Allowance is “time consumed by continued examination of the application requested by the applicant under section 132(b)” under 35 U.S.C. § 154(b)(1)(B)(i), and is excluded from B Delay, when calculating the patent term adjustment (“PTA”). In Mayo Foundation for Medical Education and Research v. Iancu, Appeal No. 2018-2031, the Court affirmed a decision from the Eastern District of Virginia which itself affirmed the USPTO’s PTA calculation, concluding that the USPTO’s interpretation of “any time consumed by continued examination of the application requested by the applicant under section 132(b)” was correct. 

By way of background, the statute for calculating PTA, 35 U.S.C. § 154(b), compensates applicants for three broad classes of delay, including what is termed “B Delay,” which generally provides PTA for each day the application is pending beyond three years after filing. Under § 154(b)(1)(B), the three-year pendency guarantee (“B Delay”) is subject to exclusions, including (relevant here): “(i) any time consumed by continued examination of the application requested by the applicant under section 132(b).” The USPTO has repeatedly promulgated regulations setting forth its interpretation of this exclusion (also known as “RCE time”).

In Novartis AG v. Lee, 740 F.3d 593 (Fed. Cir. 2014), the Federal Circuit held that the USPTO’s previous interpretation of RCE time—from the filing date of the RCE to issuance—was incorrect because, absent exceptional circumstances, “allowance-to-issuance time” is “plainly attributable to the PTO,” regardless of “whether there is a continued examination in a prosecution.” The USPTO subsequently promulgated a new regulation, interpreting RCE time as “[t]he number of days . . . beginning on [the RCE filing date] and ending on the date of mailing of the notice of allowance.”

Here, the patent issued from an application filed on April 9, 2009. The USPTO issued a final rejection of the pending claims on October 14, 2010, as anticipated. Mayo filed an RCE on September 14, 2011, along with remarks suggesting an interference.

An interference was declared on February 9, 2012. On February 19, 2014, the PTAB awarded priority to Mayo’s application. The decision became final on April 23, 2014.

The Board returned Mayo’s application to the examiner, who (on June 30, 2014) rejected Mayo’s claims on the ground of non-statutory obviousness-type double patenting. Mayo filed a reply on October 24, 2014; the examiner withdrew the rejection and mailed a Notice of Allowance on November 3, 2014. The patent issued on March 17, 2015.

The parties agreed that the time from Mayo’s filing the RCE to the declaration of interference (148 days) was RCE time, and that the duration of the interference proceeding (805 days) was not. Mayo’s appeal concerned the time from the end of the interference to the Notice of Allowance (194 days).

The USPTO calculated a PTA of 621 days, with no B Delay. Mayo argued that “[t]he examiner’s sua sponte reopening of prosecution after termination of the interference was not [RCE time].” Per Mayo, RCE time was only the above-referenced 148 days. For its part, the USPTO argued that RCE time did not end when the interference was declared, but when the Notice of Allowance was mailed. Accordingly, the USPTO calculated an additional 194 days of RCE time, between termination of the interference and mailing the Notice of Allowance. Because RCE time is deducted from B Delay, and the USPTO’s calculation of RCE time exceeded Mayo’s, the USPTO concluded there was no B Delay and Mayo was entitled to less PTA than it sought.

On appeal to the Eastern District of Virginia, the court disagreed that a declaration of an interference terminates RCE time. The court rejected Mayo’s argument that Novartis holds that continued examination ends once the claims are “deemed allowable,” not necessarily on the date of mailing of the Notice of Allowance, and that a declaration of interference is tantamount to a Notice of Allowance. Instead, the court found that Novartis established that RCE time “presumptively ends” upon mailing of the Notice of Allowance. The court also found that, because “the applicant’s requested continued examination does not presumptively end at the time the interference is declared,” declaring an interference is not analogous to resuming examination after the Notice of Allowance.

The court also rejected Mayo’s claim that the examiner’s reopening of examination after remand was attributable to the USPTO. Per the court, examination after remand was RCE time “attributable to Mayo” because “[h]ad Mayo not requested a continued examination, the PTO would not have conducted the interference proceedings . . . [or] examined the issue of double patenting.”

The Federal Circuit agreed. The Court agreed with the USPTO that a declaration of an interference does not close prosecution on the merits, and USPTO procedures and regulations contemplate that examination may continue afterward. The Court also agreed that Mayo’s rule requiring a determination of when the USPTO deems the claims allowable would turn PTA calculation into a “hotly contested factual inquiry in nearly every [ ] case.”

The Court also addressed Novartis, where it held that the time between mailing the Notice of Allowance and issuance is not RCE time, generally. The Court noted that, post remand, Mayo argued against a double patenting rejection and secured allowance. As such, “examination clearly did not end until [ ] the Notice of Allowance was mailed.”

The Court also rejected Mayo’s argument that the examiner could not have issued a rejection that “had nothing to do with any issue raised in the [RCE].” Per the Court, “Mayo requested continued examination, and that is what it received, both before and after the interference proceeding.”The Court concluded, “[W]e hold that, where an RCE has previously been filed, the time between termination of an interference and the date of mailing of the Notice of Allowance is ‘time consumed by continued examination of the application requested by the applicant under section 132(b)’ pursuant to 35 U.S.C. § 154(b)(1)(B)(i).”

Judge Newman, dissenting, agreed with Mayo that the calculation of PTA includes the period of examination after termination of the interference, saying “it plainly is examination delay due to [USPTO] procedures.”

She disputed the majority’s application of Novartis, saying that Novartis “did not relate to ongoing or continuing prosecution or any activity before mailing of the notice of allowance. Novartis was concerned only with the ‘time from allowance to issuance.’”

As for examination after remand, she noted that the interference judgment contained no recommendation for further action. In that case, per MPEP § 2308, post-interference examination was at the initiative of the examiner, not Mayo. “It is not disputed that Mayo did not request further examination.”

Finally, Judge Newman said the majority result was contrary to the statute and policy. Post-interference examination was USPTO activity, part of the examination before the notice of allowance, and thus “plainly [ ] within the purpose of the [PTA] statute.” Were post-interference activity part of interference delay, it would be included in C Delay. Either way, the adjusted term would include this period of examination.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions